Ainos to Present at MicroCap Rodeo Winter Wonderland Conference

TL;DR

**Ainos is pitching to investors at a conference, hoping to boost visibility.**

AI Summary

Ainos, Inc. filed an 8-K on February 5, 2024, to disclose that it will be making a presentation at the MicroCap Rodeo Winter Wonderland Best Ideas Conference 2024. This presentation, which includes an updated investor deck, will be available on the company's website. This matters to investors because it indicates Ainos is actively engaging with the investment community to attract capital and potentially increase its stock visibility.

Why It Matters

This filing signals Ainos, Inc.'s proactive efforts to engage with investors and raise its profile, which could lead to increased investor interest and potentially impact its stock price.

Risk Assessment

Risk Level: low — This filing is a routine disclosure about an investor presentation and does not introduce significant new risks.

Analyst Insight

A smart investor would review the updated investor presentation on Ainos, Inc.'s website to gain deeper insights into the company's strategy and prospects, as this presentation is intended to attract new capital.

Key Players & Entities

• Ainos, Inc. (company) — the registrant filing the 8-K
• MicroCap Rodeo Winter Wonderland Best Ideas Conference 2024 (event) — where Ainos, Inc. will be presenting
• February 5, 2024 (date) — date of the earliest event reported in the 8-K

Forward-Looking Statements

• Ainos, Inc. will experience increased investor interest following its presentation. (Ainos, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar

Filing Documents

• aimd_8k.htm (8-K) — 28KB
• aimd_ex991.htm (EX-99.1) — 14KB
• 0001654954-24-001299.txt ( ) — 184KB
• aimd-20240205.xsd (EX-101.SCH) — 6KB
• aimd-20240205_lab.xml (EX-101.LAB) — 16KB
• aimd-20240205_cal.xml (EX-101.CAL) — 1KB
• aimd-20240205_pre.xml (EX-101.PRE) — 12KB
• aimd-20240205_def.xml (EX-101.DEF) — 4KB
• aimd_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 5, 2024, Ainos, Inc. issued a press release announcing that it has submitted the clinical hold complete response to the U.S. Food and Drug Administration (the "U.S. FDA") for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, for treatment of mild COVID-19 symptoms. A copy of the press release is attached to this report as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. This Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as the materiality of any information in this Item 7.01 that is required to be disclosed solely by Regulation FD.

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 5, 2024, issued by the Ainos, Inc. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ainos, Inc. Date: February 5, 2024 By: /s/ Chun-Hsien Tsai Name: Chun-Hsien Tsai Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR